Derma Sciences to stop development of foot ulcer drug aclerastide

13 November 2015

Derma Sciences is to stop development of its drug aclerastide for diabetic foot ulcer healing following the advice of a Data Monitoring Committee (DMC).

The company’s decision is based on futility determinations conducted by the DMC for the pre-specified interim analyses regarding the main goal of confirmed complete wound closure of the target ulcer within 12 weeks of starting treatment.

Edward Quilty, chief executive of Derma Sciences, said: "we are very disappointed with the findings of the analyses of the DMC... we have stopped further enrolment and initiated an orderly termination of the aclerastide trials and program."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK